IDP-023

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

• IDP-023 is an off the shelf immunotherapy that is made using natural killer cells. Researchers change natural killer cells in laboratory to help them better recognize and attack cancer cells.
• Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
• Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
• Mesna is a cytoprotectant drug used to reduce the risk of bleeding from the bladder in patients receiving certain types of chemotherapy.
• Rituximab is an anti-CD20 monoclonal antibody currently approved for use in B-Cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, and several autoimmune conditions.
• Interleukin-2 is an immunotherapy drug used to treat several different indications. It works to help certain parts of your immune system to increase production of immune cells.
• Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
• Isatuximab is a type of drug called a monoclonal antibody. Isatuximab targets a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.